부산대학교 도서관

Melanoma is a neoplasia of dramatically increasing incidence that has a propensity to spread rapidly. Early detection is fundamental and patient management requires reliable, sensitive and reproducible staging methods, such as a single examination by planar scintigraphy or single-photon emission tomography (SPET) using a radiopharmaceutical with selectivity for melanoma tissue. Among iodobenzamides reported to possess an affinity for melanoma, a new compound, N-(2-diethylaminoethyl)-2-iodobenzamide (BZA[sub 2] ), was selected for a clinical trial in view of its pharmacokinetic experimental profile in melanoma-bearing mice. Planar whole-body scintigraphy using [sup 123] I-BZA[sub 2] was performed in 25 patients with histologically proven cutaneous melanoma. Performance was evaluated in two groups of patients with one or more documented secondary lesions (n=13) or with no known secondary lesions (n=12), and results were compared with those of conventional investigation techniques. No adverse clinical or biological events were recorded. Lesions were imaged by increased tracer uptake, and good quality images were obtained 4 h after administration. After a follow-up of more than 1 year, the overall results of [sup 123] I-BZA[sub 2] scintigraphy on a per patient basis showed a sensitivity of 100%, a specificity of 95%, a positive predictive value of 86% and a negative predictive value of 100%. The proven secondary lesions were imaged with a sensitivity of 100% and a specificity of 91%. In seven patients with suspected metastases, the absence of [sup 123] I-BZA[sub 2] uptake was confirmed as true negative, and in one patient without suspected metastases, [sup 123] I-BZA[sub 2] scintigraphy revealed a gastric lesion. Hence eight diagnoses would have been modified by [sup 123] I-BZA[sub 2] scintigraphy data. [sup 123] I-BZA[sub 2] allowed discrimination between benign and malignant lesions and, in the case of malignancies, between those of melanomatous origin and others... [ABSTRACT FROM AUTHOR]